-transparent.png){kind=logo}
Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents. 2001
M L Barreca, and
A Chimirri, and
L De Luca, and
A M Monforte, and
P Monforte, and
A Rao, and
M Zappalà, and
J Balzarini, and
E De Clercq, and
C Pannecouque, and
M Witvrouw
Dipartimento Farmaco-Chimico, Università di Messina, Viale Annunziata, 98168, Messina, Italy.
Design, synthesis and anti-HIV activity of a series of 2,3-diaryl-1,3-thiazolidin-4-ones are reported. Some derivatives proved to be highly effective in inhibiting HIV-1 replication at nanomolar concentrations thereby acting as non-nucleoside HIV-1 RT inhibitors (NNRTIs). SAR studies evidenced that the nature of the substituents at the 2 and 3 positions of the thiazolidinone nucleus largely influenced the in vitro anti-HIV activity of this new class of potent antiviral agents.
Related Publications
M L Barreca, and
A Chimirri, and
L De Luca, and
A M Monforte, and
P Monforte, and
A Rao, and
M Zappalà, and
J Balzarini, and
E De Clercq, and
C Pannecouque, and
M Witvrouw
January 2004,
Farmaco (Societa chimica italiana : 1989),
M L Barreca, and
A Chimirri, and
L De Luca, and
A M Monforte, and
P Monforte, and
A Rao, and
M Zappalà, and
J Balzarini, and
E De Clercq, and
C Pannecouque, and
M Witvrouw
July 2007,
Medicinal chemistry (Shariqah (United Arab Emirates)),
M L Barreca, and
A Chimirri, and
L De Luca, and
A M Monforte, and
P Monforte, and
A Rao, and
M Zappalà, and
J Balzarini, and
E De Clercq, and
C Pannecouque, and
M Witvrouw
February 2003,
Farmaco (Societa chimica italiana : 1989),
M L Barreca, and
A Chimirri, and
L De Luca, and
A M Monforte, and
P Monforte, and
A Rao, and
M Zappalà, and
J Balzarini, and
E De Clercq, and
C Pannecouque, and
M Witvrouw
November 2023,
European journal of medicinal chemistry,
M L Barreca, and
A Chimirri, and
L De Luca, and
A M Monforte, and
P Monforte, and
A Rao, and
M Zappalà, and
J Balzarini, and
E De Clercq, and
C Pannecouque, and
M Witvrouw
September 2005,
Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques,
M L Barreca, and
A Chimirri, and
L De Luca, and
A M Monforte, and
P Monforte, and
A Rao, and
M Zappalà, and
J Balzarini, and
E De Clercq, and
C Pannecouque, and
M Witvrouw
December 2004,
Journal of molecular modeling,
M L Barreca, and
A Chimirri, and
L De Luca, and
A M Monforte, and
P Monforte, and
A Rao, and
M Zappalà, and
J Balzarini, and
E De Clercq, and
C Pannecouque, and
M Witvrouw
February 1989,
Bollettino della Societa italiana di biologia sperimentale,
M L Barreca, and
A Chimirri, and
L De Luca, and
A M Monforte, and
P Monforte, and
A Rao, and
M Zappalà, and
J Balzarini, and
E De Clercq, and
C Pannecouque, and
M Witvrouw
June 1989,
Bollettino della Societa italiana di biologia sperimentale,
M L Barreca, and
A Chimirri, and
L De Luca, and
A M Monforte, and
P Monforte, and
A Rao, and
M Zappalà, and
J Balzarini, and
E De Clercq, and
C Pannecouque, and
M Witvrouw
September 2002,
Farmaco (Societa chimica italiana : 1989),
M L Barreca, and
A Chimirri, and
L De Luca, and
A M Monforte, and
P Monforte, and
A Rao, and
M Zappalà, and
J Balzarini, and
E De Clercq, and
C Pannecouque, and
M Witvrouw
September 1989,
Bollettino della Societa italiana di biologia sperimentale,
